Humana Inc. decided to include NanoString Technologies Inc.'s Prosigna breast cancer gene signature assay in its coverage.

The insurer's decision is in accordance with the ASCO guidelines, which consider Prosigna to be medically necessary in assessing whether adjuvant chemotherapy in ER-positive, HER2-negative, node-negative breast cancer patients is required, when adjuvant chemotherapy is not precluded due to any other factor.